Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older
Completed · Phase 1, Phase 2 · NCT05553301
Conditions: Influenza Immunization
At a glance
- Research payments reported, 2025
- $76,032
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 560
About the trial
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Tested
- Quadrivalent Influenza mRNA Vaccine MRT5407 (biological), Quadrivalent Recombinant Influenza Vaccine (biological), Quadrivalent Influenza Standard Dose Vaccine (biological), Quadrivalent Influenza High-Dose Vaccine (biological)
- Dates
- Started 2022-10-03; completion 2024-01-19
- Results posted
- Not yet
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 2 dose levels of Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5407 compared to an active control (QIV standard-dose (SD), QIV high-dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.
From ClinicalTrials.gov, last updated 2025-01-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi Pasteur Inc. reported $76,032 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nelia E. Sanchez-crespo, M.D. Internal Medicine · Hollywood, FL
- Mark S. Adams, M.D. Internal Medicine · London, KY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Research Centers of America $74,432
- Alliance for Multispecialty Research,llc $1,600
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.